Exonic
Latest round
- Seed
Last raised
- Nov 2025
Total raised
- Undisclosed
Investors
- 2
About Exonic
Founded in 2025 and headquartered in San Francisco, US, Exonic focuses on leveraging artificial intelligence for precision gene therapy. The company has engaged in one investment deal, with the most recent taking place on November 17, 2025.Exonic is at the forefront of precision gene therapy, leveraging artificial intelligence to enhance the efficacy and specificity of genetic interventions. The company's core offerings include advanced AI-driven platforms designed to optimize gene editing techniques, aiming to address genetic disorders with unparalleled accuracy. These platforms cater to a diverse clientele that includes research institutions, pharmaceutical companies, and biotechnology firms, providing them with tools necessary for developing targeted treatments. The products are utilized across various geographical markets, including North America, Europe, and parts of Asia, where there is significant demand for innovative gene therapy solutions.Exonic's revenue model is primarily based on partnerships with pharmaceutical and biotech companies, facilitating B2B transactions that are essential for the development of gene therapies. The company engages in collaborative agreements where clients subscribe to Exonic's AI platforms for a set duration, allowing them access to proprietary algorithms and data analytics that enhance their gene therapy research. These partnerships are structured to include milestone payments linked to the development phases of client projects, ensuring that Exonic is rewarded as its technologies contribute to successful outcomes. While specific pricing details for these services are not publicly disclosed, the business model reflects a commitment to providing high-value solutions that align with the evolving needs of the biotech sector. Exonic plans to expand its product offerings and explore new market opportunities, particularly in Europe and Asia, by the end of 2026. This strategic push aims to enhance accessibility to their AI-driven gene therapy solutions, meeting the increasing demand for advanced genetic treatments.
Who invested in Exonic
2 investors across 1 round
See all investors in Exonic
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Nov 17, 2025
Amount
Undisclosed
Investors
Questions about Exonic
Who invested in Exonic?
Exonic has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Exonic raised?
Exonic has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Exonic last raise money?
Exonic's most recent round on record is a Seed, in Nov 2025.
What does Exonic do?
Founded in 2025 and headquartered in San Francisco, US, Exonic focuses on leveraging artificial intelligence for precision gene therapy.
Where is Exonic headquartered?
Exonic is headquartered in San Francisco, US.
Which VCs invest in companies like Exonic?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Exonic's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Exonic? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.